Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cancer Metastasis Rev. 2020 Dec;39(4):1223-1243. doi: 10.1007/s10555-020-09924-4. Epub 2020 Aug 11.
Pancreatic cancer is the third leading cause of cancer death in the USA, and pancreatic ductal adenocarcinoma (PDA) constitutes 85% of pancreatic cancer diagnoses. PDA frequently metastasizes to the peritoneum, but effective treatment of peritoneal metastasis remains a clinical challenge. Despite this unmet need, understanding of the biological mechanisms that contribute to development and progression of PDA peritoneal metastasis is sparse. By contrast, a vast number of studies have investigated mechanisms of peritoneal metastasis in ovarian and gastric cancers. Here, we contrast similarities and differences between peritoneal metastasis in PDA as compared with those in gastric and ovarian cancer by outlining molecular mediators involved in each step of the peritoneal metastasis cascade. This review aims to provide mechanistic insights that could be translated into effective targeted therapies for patients with peritoneal metastasis from PDA.
胰腺癌是美国癌症死亡的第三大主要原因，而胰腺导管腺癌（PDA）构成了 85%的胰腺癌诊断。PDA 经常转移到腹膜，但有效治疗腹膜转移仍然是一个临床挑战。尽管存在这种未满足的需求，但对导致 PDA 腹膜转移的生物学机制的理解仍然很少。相比之下，大量研究已经研究了卵巢癌和胃癌中腹膜转移的机制。在这里，我们通过概述腹膜转移级联反应的每个步骤中涉及的分子介质，对比 PDA 与胃癌和卵巢癌腹膜转移之间的相似之处和不同之处。本综述旨在提供可能转化为针对 PDA 腹膜转移患者的有效靶向治疗的机制见解。
